RxDoctor Payments Data

Kailey Marshall

Optometrist · Corona, CANPI 1780065938

Payments from drug & device makers

$3,113in general payments, 2019–2025

Across 15 payments — averaging $207.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$2K
  • Glaukos Corporation$649
  • Sun Pharmaceutical Industries Inc.$183
  • Johnson & Johnson Vision Care, Inc.$142
  • Tarsus Pharmaceuticals, Inc.$125
  • Harrow Eye, LLC$119
  • plus $232 from 4 others

What the payments were for

  • Consulting fees$1,50048%
  • Speaking & faculty fees$50016%
  • Food & beverage$1,11336%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,113 in reported general payments places this provider in the 85th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$11,851
Medicare patients
104
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast79$81,335
RestasisCyclosporine63$56,954
Cyclosporine61$19,588
MieboPerfluorohexyloctane/Pf23$17,005
Prednisolone Acetate185$6,455
Loteprednol Etabonate27$6,385
IlevroNepafenac13$4,761
ValacyclovirValacyclovir Hcl29$2,300
MoxifloxacinMoxifloxacin Hcl75$2,006
Famciclovir12$1,065
Fluorometholone13$739
Latanoprost38$445
Ketorolac Tromethamine40$430
Acyclovir28$356
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$118$4,76113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,778 optometrist providers in California.

Other optometrist in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →